The capture: lawful and regulatory certainty is small. Retatrutide was never around the FDA drug shortage record (as it was hardly ever approved), so compounders providing it operate under more tenuous lawful framing than people who managed semaglutide or tirzepatide in the course of the 2023–2024 shortages. Pricing may possibly shift as enforcem